These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 10344287

  • 1. Two-dimensional electrophoresis of prostate-specific antigen in sera of men with prostate cancer or benign prostate hyperplasia.
    Charrier JP, Tournel C, Michel S, Dalbon P, Jolivet M.
    Electrophoresis; 1999; 20(4-5):1075-81. PubMed ID: 10344287
    [Abstract] [Full Text] [Related]

  • 2. Differential diagnosis of prostate cancer and benign prostate hyperplasia using two-dimensional electrophoresis.
    Charrier JP, Tournel C, Michel S, Comby S, Jolivet-Reynaud C, Passagot J, Dalbon P, Chautard D, Jolivet M.
    Electrophoresis; 2001 May; 22(9):1861-6. PubMed ID: 11425243
    [Abstract] [Full Text] [Related]

  • 3. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
    Becker C, Piironen T, Pettersson K, Björk T, Wojno KJ, Oesterling JE, Lilja H.
    J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
    [Abstract] [Full Text] [Related]

  • 4. Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease.
    Mikolajczyk SD, Rittenhouse HG.
    Rinsho Byori; 2004 Mar; 52(3):223-30. PubMed ID: 15137320
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Free to complexed PSA ratio in differentiating benign prostate hyperplasia from prostate cancer.
    Filella X, Alcover J, Corral JM, Molina R, Beardo P, Ballesta AM.
    Anticancer Res; 2001 Mar; 21(5):3717-20. PubMed ID: 11848550
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Molecular forms of serum prostate-specific antigen: the clinical usefulness of percent free PSA to discriminate prostate cancer from BPH.
    Abrahamsson PA, Kuriyama M.
    Hinyokika Kiyo; 1998 Apr; 44(4):223-32. PubMed ID: 9617617
    [Abstract] [Full Text] [Related]

  • 10. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
    Trojan L, Bode C, Weiss C, Mayer D, Grobholz R, Alken P, Michel MS.
    Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
    [Abstract] [Full Text] [Related]

  • 11. [Molecular forms of prostate-specific antigen and their clinical significance].
    Hilz H.
    Urologe A; 1995 Jul; 34(4):275-82. PubMed ID: 7545841
    [Abstract] [Full Text] [Related]

  • 12. Additional use of [-2] precursor prostate-specific antigen and "benign" PSA at diagnosis in screen-detected prostate cancer.
    de Vries SH, Raaijmakers R, Blijenberg BG, Mikolajczyk SD, Rittenhouse HG, Schröder FH.
    Urology; 2005 May; 65(5):926-30. PubMed ID: 15882725
    [Abstract] [Full Text] [Related]

  • 13. A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis.
    Lein M, Jung K, Hammerer P, Graefen M, Semjonow A, Stieber P, Ossendorf M, Luboldt HJ, Brux B, Stephan C, Schnorr D, Loening SA.
    Prostate; 2001 May 01; 47(2):77-84. PubMed ID: 11340629
    [Abstract] [Full Text] [Related]

  • 14. Dual monoclonal antibody immunoassay for free prostate-specific antigen.
    Wang TJ, Hill TM, Sokoloff RL, Frankenne F, Rittenhouse HG, Wolfert RL.
    Prostate; 1996 Jan 01; 28(1):10-6. PubMed ID: 8545276
    [Abstract] [Full Text] [Related]

  • 15. [Changes of serum total PSA and free PSA in patients with prostate carcinoma and benign prostate hyperplasia].
    Gao ZW, Liu G, Sheng BW.
    Ai Zheng; 2004 Jun 01; 23(6):701-3. PubMed ID: 15191675
    [Abstract] [Full Text] [Related]

  • 16. The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels.
    Ramos CG, Carvahal GF, Mager DE, Haberer B, Catalona WJ.
    J Urol; 1999 Nov 01; 162(5):1587-90. PubMed ID: 10524873
    [Abstract] [Full Text] [Related]

  • 17. [Prostate-specific antigen as a tumor marker of prostate carcinoma].
    Wymenga LF, Mensink HJ.
    Ned Tijdschr Geneeskd; 1999 Aug 21; 143(34):1733-8. PubMed ID: 10494319
    [Abstract] [Full Text] [Related]

  • 18. [Free/total prostate specific antigen ratio (%PSA) to predict probability of prostate cancer].
    Zenimoto M, Kita M, Arai T, Murayama T, Mori M.
    Rinsho Byori; 2003 Oct 21; 51(10):969-73. PubMed ID: 14653195
    [Abstract] [Full Text] [Related]

  • 19. Prostate tissue and serum markers.
    Mazzucchelli R, Colanzi P, Pomante R, Muzzonigro G, Montironi R.
    Adv Clin Path; 2000 Jul 21; 4(3):111-20. PubMed ID: 11080790
    [Abstract] [Full Text] [Related]

  • 20. Regulation of the enzymatic activity of prostate-specific antigen and its reactions with extracellular protease inhibitors in prostate cancer.
    Lilja H.
    Scand J Clin Lab Invest Suppl; 1995 Jul 21; 220():47-56. PubMed ID: 7544478
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.